EP1534728A4 - Modulation antisens de l'expression du recepteur de glucocorticoide - Google Patents
Modulation antisens de l'expression du recepteur de glucocorticoideInfo
- Publication number
- EP1534728A4 EP1534728A4 EP03729073A EP03729073A EP1534728A4 EP 1534728 A4 EP1534728 A4 EP 1534728A4 EP 03729073 A EP03729073 A EP 03729073A EP 03729073 A EP03729073 A EP 03729073A EP 1534728 A4 EP1534728 A4 EP 1534728A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glucocorticoid receptor
- receptor expression
- antisense modulation
- expression
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38185702P | 2002-05-20 | 2002-05-20 | |
US381857P | 2002-05-20 | ||
PCT/US2003/016084 WO2003099215A2 (fr) | 2002-05-20 | 2003-05-20 | Modulation antisens de l'expression du recepteur de glucocorticoide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1534728A2 EP1534728A2 (fr) | 2005-06-01 |
EP1534728A4 true EP1534728A4 (fr) | 2005-10-26 |
Family
ID=29584332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03729073A Withdrawn EP1534728A4 (fr) | 2002-05-20 | 2003-05-20 | Modulation antisens de l'expression du recepteur de glucocorticoide |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1534728A4 (fr) |
JP (1) | JP2005525829A (fr) |
AU (1) | AU2003233634A1 (fr) |
WO (1) | WO2003099215A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1711606A2 (fr) * | 2004-01-20 | 2006-10-18 | Isis Pharmaceuticals, Inc. | Modulation de l'expression du r cepteur glucocortico de |
EP1799859B1 (fr) * | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides antisens ameliores |
EP1941040A1 (fr) * | 2005-09-19 | 2008-07-09 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation de l'expression du récepteur glucocorticoïde |
WO2007134014A2 (fr) * | 2006-05-05 | 2007-11-22 | Isis Pharmaceuticals, Inc. | Composés et procédés de modulation de l'expression du gcgr |
JP2009171895A (ja) * | 2008-01-24 | 2009-08-06 | Hitachi Software Eng Co Ltd | 核内ノンコーディングrnaの機能解析方法 |
EP2429657A2 (fr) * | 2009-05-15 | 2012-03-21 | F. Hoffmann-La Roche AG | Compositions et procédés pour l'inhibition de l'expression de gènes de récepteurs aux glucocorticoïdes (gcr) |
EP2545173A2 (fr) * | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Modulation anti-sens de récepteurs hormonaux nucléaires |
WO2013063313A1 (fr) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Modulation antisens de l'expression de gccr |
US9234200B2 (en) * | 2011-12-15 | 2016-01-12 | National University Of Corporation Tokyo University Of Agriculture And Technology | Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector |
US10364433B2 (en) * | 2014-11-14 | 2019-07-30 | The Regents Of The University Of California | Modulation of AGPAT5 expression |
KR20210010555A (ko) * | 2018-05-17 | 2021-01-27 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 약물 저항성 면역 세포 및 그의 사용 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027986A1 (fr) * | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Agents therapeutiques et procedes de traitement du diabete de type ii et symptomes du diabete de type ii |
-
2003
- 2003-05-20 EP EP03729073A patent/EP1534728A4/fr not_active Withdrawn
- 2003-05-20 WO PCT/US2003/016084 patent/WO2003099215A2/fr not_active Application Discontinuation
- 2003-05-20 JP JP2004506742A patent/JP2005525829A/ja not_active Withdrawn
- 2003-05-20 AU AU2003233634A patent/AU2003233634A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027986A1 (fr) * | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Agents therapeutiques et procedes de traitement du diabete de type ii et symptomes du diabete de type ii |
Non-Patent Citations (7)
Title |
---|
29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE.; MIAMI BEACH, FLORIDA, USA; OCTOBER 23-28, 1999 * |
ALTMANN K-H ET AL: "NOVEL CHEMISTRY", APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, NEW YORK, WILEY-LISS, US, 1998, pages 73 - 107, XP002119324, ISBN: 0-471-17279-0 * |
HOLLENBERG S M ET AL: "PRIMARY STRUCTURE AND EXPRESSION OF A FUNCTIONAL HUMAN GLUCOCORTICOID RECEPTOR CDNA", NATURE, vol. 318, 19 December 1985 (1985-12-19), pages 635 - 641, XP000611470, ISSN: 0028-0836 * |
ISLAM A ET AL: "Antisense oligodeoxynucleotide to rat glucocorticoid receptor, given ICV in polymer microspheres, reduces glucocorticoid- and increases 5-HT2A-receptor binding", BRITISH JOURNAL OF PHARMACOLOGY, vol. 129, no. Proceedings Supplement, January 2000 (2000-01-01), pages 244P, XP008051733, ISSN: 0007-1188 * |
ISLAM A ET AL: "Antisense oligonucleotides to the rat glucocorticoid receptor (GR), optimised by RNase-H accessibility mapping of in vitro transcribed mRNA, modulate GR and 5-HT2A expression in C6 glioma cells", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 1817, XP008051792, ISSN: 0190-5295 * |
MEETING OF THE BRITISH PHARMACOLOGICAL SOCIETY; CAMBRIDGE, ENGLAND, UK; JANUARY 05-07, 2000. * |
RICHARDS D ET AL: "Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 265, no. 1 PART 2, 1993, pages R146 - R150, XP008051596, ISSN: 0002-9513 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005525829A (ja) | 2005-09-02 |
WO2003099215A3 (fr) | 2005-03-31 |
AU2003233634A8 (en) | 2003-12-12 |
WO2003099215A2 (fr) | 2003-12-04 |
EP1534728A2 (fr) | 2005-06-01 |
AU2003233634A1 (en) | 2003-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002036743A3 (fr) | Modulation antisens de l'expression de calreticuline | |
WO2004005460A3 (fr) | Modulation antisens de l'expression de la reductase de hmg-coa | |
WO2004030750A8 (fr) | Modulation antisens de l'expression du fxr (farnesoid x receptor) | |
WO2003012057A3 (fr) | Modulation antisens de l'expression du serum amyloide a4 | |
WO2004071407A3 (fr) | Modulation antisens de l'expression de ptp1b | |
WO2003052072A3 (fr) | Modulation antisens de l'expression du recepteur alpha d'oestrogene | |
WO2003010284A3 (fr) | Modulation antisens de l'expression de la proteine reactive c | |
WO2003099215A3 (fr) | Modulation antisens de l'expression du recepteur de glucocorticoide | |
EP1212456A4 (fr) | Modulation antisens de l'expression de shp-2 | |
WO2003000656A3 (fr) | Modulation anti-sens de l'expression du recepteur du facteur de croissance transformant bêta de type ii | |
WO2003105755A3 (fr) | Modulation antisens de l'expression du facteur de croissance endotheliale vasculaire c (vegf-c) | |
WO2003053341A3 (fr) | Modulation antisens de l'expression de ship-1 | |
WO2003104397A3 (fr) | Modulation antisens de l'expression de la proteine kinase gr 6 | |
WO2002095053A3 (fr) | Modulation antisens de l'expression des src-c | |
WO2003057843A3 (fr) | Procedes et materiaux de modulation de trpc4 | |
WO2003088921A3 (fr) | Modulation antisens de l'expression d'hydroxysteroide 11-beta deshydrogenase 1 | |
WO2003050244A3 (fr) | Modulation antisens de l'expression de recepteur etbr-lp-2 couple aux proteines g | |
WO2003052062A3 (fr) | Modulation antisens de l'expression de cd36l1 | |
WO2004010956A3 (fr) | Modulation par antisens d'expression de lar | |
WO2003070878A3 (fr) | Modulation anti-sens de l'expression des proteines tyrosine kinase de cellules hematopoietiques | |
WO2003057847A3 (fr) | Procedes et substances de modulation de l'enac-beta | |
WO2004016749A3 (fr) | Modulation antisens de l'expression de l'acyl-coa synthetase 1 | |
WO2004011623A3 (fr) | Modulation antisens de l'expression de la ptpra | |
WO2004015126A3 (fr) | Modulation antisens de l'expression d'edg | |
WO2003012033A3 (fr) | Modulation antisens de l'expression du partenaire 1 d'heterodimere court |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041203 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050909 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 15/11 A Ipc: 7A 61K 31/7088 B Ipc: 7C 07H 21/00 B Ipc: 7A 61P 3/00 B |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051124 |